• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Paul Melmeyer: Value Assessments Need to Take Into Account Unique Characteristics of a Disease

Video

It is incredibly important for these assessments to consider the context of the therapy, rather than just the clinical benefit that it brings, explained Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders.

It is incredibly important for these assessments to consider the context of the therapy, rather than just the clinical benefit that it brings, explained Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders.

Transcript

How important is it for value assessments to take into account the unique factors of a disease state?

It is incredibly important for these assessments to consider the context of the therapy, rather than just the clinical benefit that it brings. Of course the clinical benefit is incredibly important and it is still going to form the core of the actual value assessment. But, the context for which that therapy is actually being delivered is important because if a patient is perhaps receiving the very first therapy for their disease that they’ve ever been able to actually obtain, that is so much more important than perhaps a patient receiving a therapy for the first time but perhaps it’s the eight therapy or the ninth therapy for that disease. That first therapy is monumental. It’s revolutionary for the patient, as well as their families, their caregivers, really everyone who cares about them. So, that context is incredibly important to consider as health technology bodies are assessing the value of these therapies.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.